Vanguard Group’s Metagenomi Therapeutics MGX Stock Holding History

Vanguard Group’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$2.06M	Buy	1,270,246 +28,736	+2%	+$62.2K	﹤0.01%	3550
2025 Q3	$2.94M	Sell	1,241,510 -16,129	-1%	-$32.7K	﹤0.01%	3451
2025 Q2	$1.86M	Sell	1,257,639 -199,548	-14%	-$312K	﹤0.01%	3556
2025 Q1	$1.98M	Buy	1,457,187 +188,798	+15%	+$450K	﹤0.01%	3492
2024 Q4	$4.58M	Buy	1,268,389 +894,486	+239%	+$2.16M	﹤0.01%	3307
2024 Q3	$811K	Buy	373,903 +157,737	+73%	+$547K	﹤0.01%	3831
2024 Q2	$882K	Buy	216,166 +36,619	+20%	+$252K	﹤0.01%	3832
2024 Q1	$1.89M	Buy	+179,547	New	+$2.06M	﹤0.01%	3612

Other funds holding MGX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's MGX Position: Q4 2025 in Review

Vanguard Group increased its Metagenomi Therapeutics (MGX) stake by 2.3% in Q4 2025, buying an estimated $62.2K and bringing the position to 1,270,246 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3550.

Vanguard Group first reported a position in MGX in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.58M in Q4 2024. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

Vanguard Group held 1,270,246 shares of Metagenomi Therapeutics worth $2.06M as of Q4 2025.
Vanguard Group bought 28,736 Metagenomi Therapeutics shares in Q4 2025, an estimated $62.2K.
Metagenomi Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3550 holding.
Vanguard Group first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 8 quarters since.
Vanguard Group's Metagenomi Therapeutics position peaked at $4.58M in Q4 2024.
56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.